4 hours Ago By ABMN Staff
Oppenheimer began coverage on shares of Alumis ( NASDAQ:ALMS – Free Report ) in a research report report published on Thursday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $32.00 price objective on the stock.
A number of other analysts also recently weighed in on ALMS. Baird R W upgraded Alumis to a “strong-buy” rating in a report on Thursday, October 31st. Robert W.
Baird initiated coverage on Alumis in a research note on Thursday, October 31st. They issued an “outperform” rating and a $25.00 price target for the company.
Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $26.00 target price on shares of Alumis in a report on Monday, January 6th.
Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $27.
57. View Our Latest Stock Analysis on Alumis Alumis Price Performance Hedge Funds Weigh In On Alumis A number of institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets acquired a new position in shares of Alumis during the 3rd quarter valued at $27,000.
MetLife Investment Management LLC acquired a new position in shares of Alumis during the third quarter valued at about $89,000. China Universal Asset Management Co. Ltd.
bought a new position in shares of Alumis during the 4th quarter worth about $79,000. JPMorgan Chase & Co. acquired a new stake in shares of Alumis in the 3rd quarter valued at about $191,000.
Finally, Barclays PLC bought a new stake in Alumis in the 3rd quarter valued at about $197,000. Alumis Company Profile ( Get Free Report ) Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system.
We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. Further Reading Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter .
.
